Meeting
2023 ASCO Annual Meeting
Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.
Authors
Masayuki Shirasawa
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Masayuki Shirasawa , Tatsuya Yoshida , Kouya Shiraishi , Shigehiro Yagishita , Yuji Matsumoto , Ken Masuda , Yuki Shinno , Yusuke Okuma , Yasushi Goto , Hidehito Horinouchi , Katsuhiko Naoki , Takaaki Tsuchida , Ryuji Hamamoto , Noboru Yamamoto , Noriko Motoi , Takashi Kohno , Shun-ichi Watanabe , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8586)
DOI
10.1200/JCO.2023.41.16_suppl.8586
Abstract #
8586
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Genomic analysis and prediction of therapeutic vulnerabilities of small cell lung cancer from rovalpituzumab tesirine phase III trial (MERU).
First Author: Weilong Zhao
Poster
2024 ASCO Annual Meeting
Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).
First Author: Himisha Beltran
Poster
2024 ASCO Annual Meeting
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER).
First Author: Nicholas I. Simon
Poster
2024 ASCO Annual Meeting
Contribution of the microbiome to differential drug efficacy and clinical trial outcomes between the US and Japan.
First Author: Jie (James) Min Lam